Press Release



DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.

CONTACT	
INVESTOR RELATIONS	MEDIA RELATIONS
SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135)	CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121)

 $\ \, \tilde{0}\,\,\tilde{0}$

Dr. Reddy's Laboratories announces

Hyderabad, India, 16 February 2017

For Immediate Release

Hyderabad, India and Princeton, NJ, USA. 16 February 2017 - Dr. Reddy s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that On February 14, 2017, the United States District Court for the District of New Jersey issued its opinion regarding Helsinn Healthcare's patent infringement claims against Dr. Reddy's Laboratories proposed palonosetron product, pursuant to a paper NDA under Section 505(b)(2) of the Food, Drug and Cosmetic Act.

The court found that Dr. Reddy's proposed palonosetron hydrochloride 0.25 mg / 5 ml product infringes certain claims of U.S. Patent Nos. 7,947,724, 8,729,094 and 9,066,980, and that the asserted claims of the 094 and 980 Patents were not invalid.

A company spokesperson stated We are disappointed in the decision and intend to pursue an appeal in due course.

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products . Dr. Reddycs offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddyt operates in markets across the globe. Our major markets include. USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the managements current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forwardlooking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.